Evidence map›Paper›PMID 25891866›Full record

ArticleCroatian medical journal2015

Protective effect of resveratrol against caspase 3 activation in primary mouse fibroblasts.

Zsófia Ulakcsai, Fruzsina Bagaméry, István Vincze, Éva Szökő, Tamás Tábi

Open access · diamondAbstract read
In one paragraph

Article in Croatian medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zsófia Ulakcsai
Fruzsina Bagaméry
István Vincze
Éva Szökő
Tamás TábiTamas Tábi, Nagyvarad ter 4, Budapest, H-1089, Hungary, tabi.tamas@pharma.semmelweis-univ.hu.
Semmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study the effect of resveratrol on survival and caspase 3 activation in non-transformed cells after serum deprivation.

methodsApoptosis was induced by serum deprivation in primary mouse embryonic fibroblasts. Caspase 3 activation and lactate dehydrogenase release were assayed as cell viability measure by using their fluorogenic substrates. The involvement of PI3K, ERK, JNK, p38, and SIRT1 signaling pathways was also examined.

resultsSerum deprivation of primary fibroblasts induced significant activation of caspase 3 within 3 hours and reduced cell viability after 24 hours. Resveratrol dose-dependently prevented caspase activation and improved cell viability with 50% inhibitory concentration (IC50)=66.3±13.81 μM. It also reduced the already up-regulated caspase 3 activity when it was added to the cell culture medium after 3 hour serum deprivation, suggesting its rescue effect. Among the major signaling pathways, p38 kinase was critical for the protective effect of resveratrol which was abolished completely in the presence of p38 inhibitor.

conclusionResveratrol showed protective effect against cell death in a rather high dose. Involvement of p38 kinase in this effect suggests the role of mild stress in its cytoprotective action. Furthermore due to its rescue effect, resveratrol may be used not only for prevention, but also treatment of age-related degenerative diseases, but in the higher dose than consumed in conventional diet.

Indexed as

AnimalsAntioxidantsApoptosisCaspase 3Cells, CulturedCell SurvivalDose-Response Relationship, DrugEmbryo, MammalianFibroblastsL-Lactate DehydrogenaseMAP Kinase Signaling SystemMicePhosphatidylinositol 3-KinasesResveratrolSignal TransductionSirtuin 1AntioxidantsCaspase 3L-Lactate DehydrogenasePhosphatidylinositol 3-KinasesResveratrolSirt1 protein, mouseSirtuin 1Stilbenes

Identifiers

PMID25891866
PMCPMC4410169
OpenAlexW2398772330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.